Intersect ENT — Investor Presentation (January 2015)
28 slides from Intersect ENT's investor presentation, Jan 12, 2015
Slide 1: Lisa Earnhardt, President & CEO
Lisa Earnhardt, President & CEO NASDAQ: XENT JANUARY 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements
Slide 3: Advancing Clinically-Proven Therapies for Ear, Nose and Throat
ADVANCING CLINICALLY-PROVEN THERAPIES for Ear, Nose and Throat (ENT) Physicians and Patients Focus on Chronic Sinusitis (CS) 29M Patients in US IMPROVING QUALITY OF LIFE from Surgery to Office Care
Slide 4: Chronic Sinusitis: Significant Unmet Need
Chronic Sinusitis: Significant Unmet Need DEBILITATING INFLAMMATORY CONDITION in 8 Adults 3.5M Managed by ENT 500,000+ Surgeries / Year Top 10 Most Costly Condition for US Employers
Slide 5: 1st Two Commercial Products
1st Two Commercial Products 1st Drug-Eluting Implants for Chronic Sinusitis Only PMA 50,000+ Patients Approval for CS to Date IMPROVING SURGICAL OUTCOMES Reduced Inflammation, Scarring and Need for Additional Surgery and Oral Steroids
Slide 6: Intersect ENT Opportunity
Intersect ENT Opportunity LARGE MARKET $4.8B TAM in US UNIQUE 1st and Only Drug Eluting PRODUCTS Implants in ENT PRODUCT In-Office Products to Serve PIPELINE Continuum of Care TRACK Strong Revenue Growth RECORD and Gross Margins (70+%) ANNUAL REVENUE ($M) $38.4- 38.6* $18 $6 2012 2013 2014E* *Prelim
Slide 7: CS Treatment Pathway
CS Treatment Pathway MEDICATION TO TREAT Oral Steroids Reduce Inflammation but Cause Side Effects SURGERY TO OPEN (FESS) Surgery Opens Pathways but Can Result in Post-Operative Scarring and Inflammation MANAGEMENT TO MAINTAIN Within One Year, 64% Symptom Recurrence and 10% Revision Surgery Challenge
Slide 8: Our Solution Portfolio
Our Solution Portfolio MEDICATION SURGERY MANAGEMENT TO TREAT TO OPEN TO MAINTAIN Local Drug Delivery via Bioabsorbable Implant Technology NOVA PROPEL RESOLVE Office Treatment for Treatment to Improve Office Treatment for Primary CS Surgical Outcomes Recurrent CS
Slide 9: Our Solution Portfolio: Commercial Therapies
Our Solution Portfolio: Commercial Therapies SURGERY TO OPEN PROPEL Treatment to Improve Surgical Outcomes
Slide 10: PROPEL / PROPEL MINI
PROPEL / PROPEL MINI How It Works ETHMOID SINUS Advanced into Surgically Enlarged Sinus Cavity
Slide 11: PROPEL / PROPEL MINI
PROPEL / PROPEL MINI How It Works ETHMOID SINUS Advanced into Surgically Enlarged Sinus Cavity OPENS Self-expanding Implant Conforms to and Holds Open Sinus DELIVERS Sustained, Targeted Delivery of Steroid Over 30 Days MAINTAINS Opening by Reducing Post-operative Inflammation and Scarring
Slide 12: PROPEL: Clinically Proven Surgical Outcomes
PROPEL Clinically Proven Surgical Outcomes Reduction in Post-Operative Medical and Surgical Interventions Meta-Analysis of Two Prospective, Multicenter, Randomized, Controlled, Double-Blind Studies Prospective Trials, 200+ Patients Only Device Used in Sinus Surgery Backed by Level 1a Evidence POST-O
Slide 13: PROPEL: Commercial Success
PROPEL Commercial Success REVENUE ($M) $ 13.2 $ 13.4 $8.5 $ 9.1 $7.0 $7.5 $4.2 Q313 Q413 Q114 Q214 Q314 Q414E* 91% Q414 vs. Q413 ADOPTION in 5 Accounts in 6 Sinus Surgeons in 20 Patients Early in Adoption Cycle SALESFORCE REIMBURSEMENT US Only FESS ~$14K 52 Territory Managers Propel treated as 10,00
Slide 14: PROPEL MINI: Expanding Indications
PROPEL MINI Expanding Indications Seeking Expanded Indication for Placement in Frontal Sinus 25% of Sinus Surgeries FRONTAL SINUS PROGRESS Currently Enrolling Prospective, Randomized, Blinded, Multi-Center Trial 80 Patients, 12 Sites GOAL Demonstrate Reduction in Need for Post-Operative Intervention
Slide 15: Our Solution Portfolio: In-Office Therapies
Our Solution Portfolio: In-Office Therapies MEDICATION TO TREAT NOVA Office Treatment for Primary CS MANAGEMENT TO MAINTAIN RESOLVE Office Treatment for Recurrent CS
Slide 16: RESOLVE: How It Works
RESOLVE How It Works IN-OFFICE POST SURGICAL TREATMENT For Patients with Refractory CS/Polyps Dilates Obstructed Cavity, Delivers Steroid Over 90 Days Less Invasive, More Cost Effective vs. Revision Surgery ETHMOID SINUS Ethmoid Sinus Immediately 6 Weeks Pre-implant Post-implant Post-implant Investi
Slide 17: RESOLVE: Promising Results
RESOLVE Promising Results Reduction in Polyp Burden and Patient Symptoms Prospective, Multicenter, Randomized, Controlled, Blinded 100 Patient Study Three Trials Complete: Pilot (12), PK Study (5), RESOLVE (100) CHANGE IN BILATERAL POLYP GRADE -0.2 -0.4 Treatment Control -0.6 -0.8 -1 p<0.05 CHANGE I
Slide 18: RESOLVE: IND Clinical Program
RESOLVE IND Clinical Program STUDY DESCRIPTION N SITES PUBLISHED Non-Randomized PILOT Open Label 12 4 Single Cohort Non-Randomized PHARMACOKINETIC Open Label 5 1 (PK) Single Cohort Phase II / III RESOLVE Randomized 1:1 100 18 Blinded Implants vs. Sham Procedure Phase III Randomized 2:1 RESOLVE II 30
Slide 19: NOVA: How It Works
NOVA How It Works IN-OFFICE PRIMARY CS SOLUTION De Novo Patients Following Balloon Dilation Hourglass Profile to Maximize Tissue Apposition and Support Feasibility Study Enrolled (15 Patients, 2 US Sites); PMA path FRONTAL AND MAXILLARY SINUSES Investigational Device Only. Not approved for sale in U
Slide 20: Large CS Market Opportunity
Large CS Market Opportunity SURGICAL 540K Patients 2-4 Implants / Surgery $700 PROPEL ASP $830M NOVA $2.8B $4.8B PRIMARY in US 2.3M Patients $1.1B RESOLVE REFRACTORY 770K Patients
Slide 21: Industry Landscape
Industry Landscape MEDICATION SURGERY MANAGEMENT TO TREAT TO OPEN TO MAINTAIN STEROIDS SURGICAL TOOLS / SUPPLIES We Are a Unique Solution – Complementary to Other Technologies
Slide 22: Multiple Barriers to Entry
Multiple Barriers to Entry CLINICAL Level 1A Clinical Evidence Award Winning Clinical Science 15 Peer-Reviewed Publications REGULATORY Only Drug Eluting Implants in ENT Two PMA Approvals RESOLVE: NDA Pathway INTELLECTUAL PROPERTY 51 Issued Patents (28 US / 23 OUS) 39 Pending Patents (13 US / 26 OUS)
Slide 23: 2015 Outlook
2015 Outlook REVENUE ($M) $60-70 $38.4-3 8.6* $18 $6 2012 2013 2014E* 2015 Plan Sales Force Growth ~40% to ~75 Territory Managers by End 2015 2015 Forecast Gross Margin 76-78% 2015 Forecast Operating Expense $74—$76M *Preliminary estimate based on currently available information. Has not been audite
Slide 24: Strong Base to Drive Forward Revenue
Strong Base to Drive Forward Revenue CONSISTENT ANNUALIZED SALES/TERRITORY MGR ($000) $1,200 60 $1,000 50 $800 40 $600 30 $400 20 $200 10 $- 0 Q1 Q2 Q3 Q4E* Ending # of TMs Annualized Sales/TM GROWING BASE OF RECURRING REVENUE ($M) $16 $14 $12 $10 $8 85% $6 $4 $2 $0 Q1 Q2 Q3 Q4E* New Reorder *Prelim
Slide 25: Milestones
Milestones GROWTH 2015 2016 2017 2018 LEVERS Commercial Ongoing Execution PROGRESS PROPEL Clinical Frontal Indication Frontal PMA-S Indication Approval Enrollment Complete International Lay OUS Groundwork RESOLVE II RESOLVE II RESOLVE Clinical Enrollment Enrollment Approval NDA Commenced Complete Fe
Slide 26: Experienced Leadership
Experienced Leadership MANAGEMENT TEAM LISA EARNHARDT President & CEO JERI HILLEMAN RICH KAUFMAN CFO COO, SVP R&D & Operations ROB BINNEY JAMES STAMBAUGH VP Sales VP Clinical & Reimbursement SUSAN STIMSON AMY WOLBECK VP Marketing VP Regulatory Affairs & Quality EXPERIENCE INCLUDES
Slide 27: $4.8B US Market
$4.8B US Market 1st and ONLY Drug Eluting Implants in ENT EMERGING In-Office Portfolio TRACK RECORD Strong Revenue Growth & GMs
Slide 28: Intersect ENT
intersect’ ENT NASDAQ: XENT